FIELD: medicine.
SUBSTANCE: invention refers to medicine, oncology, cardiology and may be used for the prediction of a cumulative cardiac toxicity of anthracycline chemotherapeutic preparations. The intravenous administration of anthracycline 50 mg/m2 is preceded and further followed 1 hour later by an examination of left ventricular ejection fraction with using planar ECG-gated equilibrium radionuclide ventriculography by standard technique. A decrease of the left ventricular ejection fraction in response to the first administration of the preparation 10% and more as compared to the reference, the cumulative cardiac toxicity is predicted.
EFFECT: method enables predicting the developing cumulative cardiac toxicity in the patient after one anthracycline chemotherapeutic course, having sensitivity 50% and specificity 92% that enables initiating the prevention of cardiologic complications promptly that develop in various time intervals of the tumour treatment.
2 ex, 6 dwg
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREVENTING ANTHRACYCLINE CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER | 2014 |
|
RU2546399C1 |
METHOD FOR PREDICTION OF SUBACUTE ANTHRACYCLINE-MEDIATED CARDIOTOXICITY DEVELOPMENT IN ONCOLOGICAL PATIENTS | 2020 |
|
RU2744682C1 |
METHOD FOR PREDICTION OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN WOMEN WITH BREAST CANCER | 2019 |
|
RU2714683C1 |
METHOD FOR PREDICTING THE DEVELOPMENT OF CARDIOTOXICITY IN PATIENTS WITH HER2 POSITIVE BREAST CANCER OF INITIALLY LOW / MODERATE CARDIOVASCULAR RISK RECEIVING A TARGETED THERAPY WITH TRASTUZUMAB AFTER ANTHRACYCLINE-CONTAINING CHEMOTHERAPY | 2020 |
|
RU2741371C1 |
METHOD FOR PERSONALIZED SELECTION OF PATIENTS WITH ANTHRACYCLINE-INDUCED CARDIOMYOPATHY AFTER POLYCHEMOTHERAPY OF BREAST CANCER FOR EFFECTIVE TREATMENT WITH CARVEDILOL | 2021 |
|
RU2778612C1 |
METHOD FOR PREDICTING PROGRESSION OF ANTHRACYCLINE-INDUCED CHRONIC HEART FAILURE IN PATIENTS WITH BREAST CANCER WITHIN 24 MONTHS | 2022 |
|
RU2793672C1 |
METHOD FOR PREDICTING DEVELOPMENT OF CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER WITHIN 12 MONTHS AFTER CHEMOTHERAPY WITH ANTRACYCLIC DRUGS | 2018 |
|
RU2680139C1 |
METHOD FOR PRODUCING ULTRASONIC ANTRACYCLINE- INDUCED CARDIOTOXICITY EVALUATION IN ONCOLOGICAL PATIENTS | 2002 |
|
RU2225166C2 |
METHOD FOR USING VASOPRESSIN ANTAGONISTS WITH ANTRACYCLINE CHEMOTHERAPEUTIC AGENTS WITH REDUCED CARDIOTOXICITY AND/OR IMPROVED SURVIVAL RATE | 2008 |
|
RU2470643C2 |
METHOD FOR TREATMENT OF CHRONIC LYMPHOLEUKOSIS | 2003 |
|
RU2243774C1 |
Authors
Dates
2014-03-27—Published
2012-04-03—Filed